of 6
1
Materials
Design
Analysis
Reporting (MDAR)
Checklist for Authors
The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life scien
ces
(see Statement of Task: doi:10.31222/osf.io/9sm4x.
). The MDAR checklist is a tool for authors, editors
, and others seeking to adopt
the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document
for additional context for the MDAR framework.
2
For all that apply, please note where in the manuscript the required infor
mation is provided.
Materials:
Newly created materials
indicate where provided: page no/section/legend)
n/a
The manuscript includes a dedicated "materials
availability statement" providing transparent
disclosure about availability of newly created
materials including details on how materials c
an be
accessed and describing any restrictions on access.
Section: Ref
erences and Notes (main text)
Data and materials availability statement
Antibodies
indicate where provided: page no/section/legend)
n/a
For commercial reagents, provide supplier name,
catalogue number and
RRID
, if available.
Goat Anti
-
Human IgG(H+L)
-
HRP SouthernBiotech
Cat#2015-
05; RRID: AB_2795588
Goat Anti
-Mouse IgG H&L (ab6708)
CD4
-APC
-eFluor 780 (clone: RM4
-5) Invitrogen
Catalog
# 47-
0042-
82
F4/80-
APC
-eFluor 780 (clone: BM8),
Invitrogen
Catalog
# 47-
4801-
82
CD8a
-APC
-eFlu
or 780 (clone: 53-
6.7),
Invitrogen
Catalog
# 47-
0081-
82
Ly-
6G
-APC
-eFluor 780 (clone: RB6
-8C5), IgM
- APC
-
eFluor 780 (clone: II/41)
Invitrogen
Catalog # 47-
5931-
82
CD19-
FITC (clone: 6D5) (Biolegend), Catalog #
115506IgG1 BV421 (clone: X40) (BD
Bioscience).
Catalog # 562438
IgG2 BV421 (clone: R19-
15)
(BD Bioscience).
Catalog # 565817
DNA and RNA sequences
indicate where provided: page no/section/legend)
n/a
Short novel
DNA or RNA
including primers, probes
:
Sequences
should be included or deposited in a
public repository.
n/a
x
Cell materials
indicate where provided: page no/section/legend
n/a
Cell lines:
Provide species information, strain.
Provide accession number in repository
OR
supplier
name, catalog number, clone number,
OR
RRID
.
H
EK293T cells
,
RRID: CVCL_0063
HEK293TAce2 cells provided by Robbiani et al., 2020
http://biorxiv.org/lookup/doi/10.1101/2020.05.
13.092619
Expi293F cells GIBCO RRID: CVCL_D615
Primary cultures:
Provide species, strain, sex of
origin, genetic modification statu
s.
n/a
x
Experimental animals
indicate where provided: page no/section/legend)
n/a
Laboratory animals
or Model organisms
:
Provide
species, strain, sex, age, genetic modification status
.
Provide
a
ccession number in repository
OR
supplier
name, catalog number, clone number,
OR
RRID
.
4- 6 week old female Balb/c mice (Charles River
Laboratories)
Animal observed in or captured from the field:
Provide species, sex
, and age where possible
.
n/a
x
Plants and microbes
indicate where provided: page no/section/legend)
n/a
3
Plants:
provide species and strain,
ecotype and
cultivar where relevant
, unique accession number if
available, and source (including location for collected
wild specimens)
.
n/a
x
Microbes:
provide species and strain, unique
accession number if available, and source
.
SARS
-
CoV
-
2 pseudotyped reporter virus
;
K. H. D.
Crawford
et al.
, Protocol and Reagents for Pseudotyping
Lentiviral Particles with SARS
-CoV
-2 Spike Protein for
Neutralization Assays.
Viruses
12
, 513 (2020).
SARS-
CoV pseudotyped reporter virus
SHC014-
CoV pseudotyped reporter virus
WIV1
-CoV pseudotyped reporter virus
E.
coli
DH5 Alpha Zymo Research Cat#T3009
E. coli
BL21-
CodonPlus Competent Cells
Agilen
Cat#230280
Human research participants
indicate where provided: page no/section/legend)
or
state if these demographics were not collected
n/a
If collected and within the bounds of privacy
constraints report on age
,
sex and gender
or
ethnicity
for all study participants.
n/a
x
Design
:
Study protocol
indicate where
provided: page no/section/legend)
n/a
If study protocol has been pre
-
registered, provide
DOI.
For clinical trials, provide the trial registration
number
OR
cite DOI.
n/a
x
Laboratory protocol
indicate where provided: page
no/section/legend)
n/a
Provide DOI
OR
other citation details if detailed step
-
by
-step protocols are available.
n/a
x
Experimental study design (statistics details)
For in vivo studies
:
State whether and how the
following have been done
indicate where provided: page no/section/legend. If it
could have been done, but was not, write not done
n/a
Sample size determination
For animal experiment in Fig. 3,
10 animals were used
per group to give a sufficient sample size for evaluating
potentially
subtle differences in immune responses.
Randomisation
n/a
x
Blinding
n/a
x
Inclusion/exclusion criteria
n/a
x
Sample definition and
in
-
laboratory replication
indicate where provided: page no/section/legend
n/a
State number of times the experiment was
replicated in laboratory
.
Animal experiment in Fig. 3. was performed once
using
cohorts of mice (10 mice per group)
.
Define whether data describe technical or biological
replicates
.
ELISAs and neutralizations for
sera from
each
animal
at
time points indicated in Fig. 3 w
ere pe
rformed in
duplicate. Each dot f
or AUC or ID50 represents the
average of each duplicate.
4
Ethics
indicate where provided: page no/section/legend
n/a
Studies involving human participants:
State details
of authority granting ethics approval (IRB or
equivalent committee(s), provide reference number
for approval.
n/a
x
Studies involving experimental animals:
State
details of authority granting ethics approval (IRB or
equivalent committee(s), provide reference number
for approval.
Animal procedures and experiments were performed
according to protocols approved by the IACUC protocol
IA19
-1725.
x
Studies involving specimen and field samples:
State
if relevant permits obtained, provide details of
authority approving study; if none were required,
explain why.
n/a
x
Dual Use Research of Concern (DURC)
indicate where provided: page
no/section/legend
n/a
If
study is subject to dual use research of
concern
regulations
, state the authority granting approval
and reference number for the regulatory approval.
n/a
x
Analysis
:
Attrition
indicate where provided: page
no/section/legend
n/a
Describe whether exclusion criteria were
preestablished. Report if sample or data points were
omitted from analysis. If yes report if this was due to
attrition or intentional exclusion and provide
justification.
n/a
x
Statistics
indicate where provided: page no/section/legend
n/a
Describe statistical tests used and justify choice of
tests.
Comparisons between groups for ELISAs and
neutralization assays were calculated with one
-way
analysis of variance (ANOVA) using Tukey’s post hoc
test.
Data
a
vailability
indicate where provided: page no/section/legend
n/a
For newly created and
reused datasets, the
manuscript includes a data availability statement
that provides details for access or notes restrictions
on access.
n/a
x
If newly created
data
sets
are publicly available,
provide accession number in repository
OR
DOI
OR
URL and licensing details where available.
n/a
x
If
reused data is
publicly available provide accession
number in repository
OR
DOI
OR
URL,
OR
citation.
n/a
x
Code
availability
indicate where provided: page no/section/legend
n/a
For all newly generated custom computer
code/software/mathematical algorithm or re
-used
code essential for replicating the main findings of
the study, the manuscript includes a data availability
statement that provides details for access or notes
restrictions.
n/a
x
If newly generated code is publicly available, provide
accession number in repository,
OR
DOI
OR
URL and
licensing details where available. State any
n/a
x
5
restrictions on code availability or accessibility
.
If reused code is
publicly available provide accession
number in repository
OR
DOI
OR
URL,
OR
citation.
n/a
x
6
Reporting
MDAR framework recommends adoption of discipline
-specific guidelines, established and endorsed through community
initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.
Adherence to community standards
indicate where provided: page no/section/legend
n/a
State if relevant guidelines (e.g., ICMJE, MIBBI,
ARRIVE) have been followed, and whether a checklist
(e.g., CONSORT, PRISMA, ARRIVE) is provided with
the manuscript.
n/a